J 2017

Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ et. al.

Basic information

Original name

Tamoxifen-Dependent Induction of AGR2 Is Associated with Increased Aggressiveness of Endometrial Cancer Cells.

Authors

HRSTKA, Roman, Ján PODHOREC, Rudolf NENUTIL, Lucia SOMMEROVÁ, Joanna Agnieszka OBACZ, Michal ĎURECH, Jakub FAKTOR, Pavel BOUCHAL, Hana SKOUPILOVÁ and Bořivoj VOJTĚŠEK

Edition

Cancer Investigation, Marcel Dekker, 2017, 0735-7907

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.053

Organization unit

Faculty of Science

UT WoS

000401553900003

Keywords in English

AGR2; Breast cancer; Endometrial cancer; Tamoxifen

Tags

Tags

International impact, Reviewed
Změněno: 24/4/2019 14:16, Mgr. Tereza Miškechová

Abstract

V originále

Tamoxifen treatment in breast cancer patients is associated with increased risk of endometrial malignancies. Significantly, higher AGR2 expression was found in endometrial cancers that developed in women previously treated with tamoxifen compared to those who had not been exposed to tamoxifen. An association of elevated AGR2 level with myometrial invasion occurrence and invasion depth was also found. In vitro analyses identified a stimulatory effect of AGR2 on cellular proliferation. Although adverse tamoxifen effects on endometrial cells remain elusive, our work identifies elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer.

Links

GA17-05957S, research and development project
Name: Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu
Investor: Czech Science Foundation